INTRODUCTION {#s1}
============

Depression has displayed an increasing trend in recent years. Pregnancy increases the chance of developing depression, namely, postpartum depression (PPD). From pregnancy and childbirth to postpartum, women encounter not only enormous physiological changes but also great psychological impacts. The prevalence rates of PPD are approximately 13.8%--19.8% in the USA \[[@R1]\]. and approximately 11.6%--25% in other countries \[[@R2]--[@R4]\]. Studies in Taiwan have demonstrated that 36.3%--42.6% of pregnant women in the Taiwan area have PPD symptoms \[[@R5]--[@R7]\]. Therefore, the chance of developing PPD is high for women in Taiwan, and this problem requires urgent attention. In the serial editions of Diagnostic and Statistical Manual of Mental Disorders (including DSM-III, DSM-III-R, DSM-IV, DSM-IV-TR, and DSM-5) noted that PPD is defined as the onset of mood disorders starting at postpartum 4 weeks. At least 5 symptoms appear every day: depressed mood, obvious lack of interest in usual activities, a decrease or increase in body weight, insomnia or excessive sleep, slow action or increased activities due to uneasiness, fatigue or decreased energy, feelings of worthlessness or guilt, diminished abilities of thinking or concentration, and occurrence of thoughts of suicide. These symptoms persist for more than two weeks \[[@R8], [@R9]\]. Some scholars consider that in addition to the mental illness diagnosis and the presentation of symptoms described in the statistical manual, PPD should also cover self-consciousness of being incapable of the roles, functions, and responsibilities of motherhood, feeling guilty, using more invasive or negative methods in child-rearing (even having thoughts and behaviors of hurting the child when having problems with one\'s parenting style after birth), changes in the spousal relationship, and the inability to concentrate on routine matters \[[@R10]--[@R13]\]. Therefore, identifying methods to reduce the development of PPD is very important.

Studies on PPD have increased in number in the past twenty to thirty years, with most studies focusing on risk factors. A few studies have noted that poor postpartum sleep quality can easily increase the risk of PPD \[[@R14], [@R15]\]. Sleep troubles in pregnant women not only affect their ability to fulfill their multiple postpartum roles but also negatively influence the development of the parent-child relationship \[[@R16], [@R17]\]. Current PPD studies in Taiwan mainly focus on nursing care; most studies have investigated the effects of PPD on the quality of life of women from psychological, family, and social perspectives \[[@R18]--[@R20]\]. Although numerous studies on sleep quality in Taiwan have been reported, few studies have investigated sleep disorders (SD) using pregnant women as the study subjects.

Currently, few reports on sleep assessment targeting pregnant women during pregnancy exist, and no systemic studies have assessed the association between SD and PPD. Therefore, we used the National Health Insurance Research Database (NHIRD) of Taiwan to perform a follow-up study on whether prenatal SD can increase the development of PPD.

RESULTS {#s2}
=======

Our study presents that there is no Statistical significance in age, number of births, comorbidities and insured premium both in subjects and control groups. (data not shown).

Figure [1](#F1){ref-type="fig"} presents the flowchart for the study sample selection (inclusion and exclusion), follow-up results and the cumulative risks of developing PPD in these two groups (pregnant women with/without SD). Among 1 million individuals, 980,157 had medical records (outpatient, emergency, or inpatient). In total, 20,140 pregnant women with SD were identified. After employing the exclusion conditions (10,302 were excluded), a total of 9,838 pregnant women with SD (19,676 controls were selected using the 1:2 ratio) were included in this study. Of these women, 0.20% developed PPD (20/9,838 people). The percentage of women who developed PPD in the control group (pregnant women without SD) was 0.05% (10/19,676 people). The difference between these two groups reached significance (log-rank *P* \< 0.001). Thus, the chance (i.e., risk) of developing PPD in pregnant women with SD was significantly increased compared with pregnant women without SD (Figure [2](#F2){ref-type="fig"}).

![The flowchart of study sample selection from National Health Insurance Research Database in Taiwan](oncotarget-09-25304-g001){#F1}

![Kaplan--Meier for cumulative risk of postpartum depression among pregnancy woman aged 18--50 after deliver in 1-year tracking stratified by sleep disorder with log-rank test](oncotarget-09-25304-g002){#F2}

Table [1](#T1){ref-type="table"} presents the distribution of the basic characteristics of the 29,514 cases overall (subject group: 9,838 pregnant women with SD; control group: 19,676 pregnant women without SD) at the follow-up endpoint. The percentage of women who developed PPD in the subject group was significantly increased compared with the control group (0.20% vs. 0.05%; *P* \< 0.001).

###### Characteristics of study at the endpoint

  Sleep disorder                Total          With    Without        *P*                            
  ----------------------------- -------------- ------- -------------- ------- -------------- ------- ----------
  **Total**                     29,514                 9,838          33.33   19,676         66.67   
  **Postpartum depression**                                                                          \< 0.001
  Without                       29,484         99.90   9,818          99.80   19,666         99.95   
  With                          30             0.10    20             0.20    10             0.05    
  **Age (years)**               35.50 ± 7.32           35.73 ± 7.05           35.25 ± 7.43           0.069
  **Age group (years)**                                                                              0.167
  ≦ 20                          997            3.38    332            3.37    665            3.38    
  21--30                        7,309          24.76   2,437          24.77   4,872          24.76   
  31--34                        6,406          21.70   2,135          21.70   4,271          21.71   
  35--37                        4,560          15.45   1,520          15.45   3,040          15.45   
  38--40                        5,373          18.20   1,794          18.24   3,579          18.19   
  ≧ 41                          4,869          16.50   1,620          16.47   3,249          16.51   
  **Number of births**          1.82 ± 1.77            1.82 ± 1.80            1.82 ± 1.74            0.548
  **Number of births**                                                                               0.999
  1 (First-time birth)          19,161         64.92   6,387          64.92   12,774         64.92   
  ≧ 2                           10,353         35.08   3,451          35.08   6,902          35.08   
  **Hypertension**                                                                                   \< 0.001
  Without                       28,254         95.73   9,217          93.69   19,037         96.75   
  With                          1,260          4.27    621            6.31    639            3.25    
  **DM**                                                                                             \< 0.001
  Without                       28,519         96.63   9,380          95.34   19,139         97.27   
  With                          995            3.37    458            4.66    537            2.73    
  **Hyperlipidemia**                                                                                 \< 0.001
  Without                       29,153         98.78   9,634          97.93   19,519         99.20   
  With                          361            1.22    204            2.07    157            0.80    
  **COPD**                                                                                           \< 0.001
  Without                       28,944         98.07   9,457          96.13   19,487         99.04   
  With                          570            1.93    381            3.87    189            0.96    
  **CKD**                                                                                            0.216
  Without                       29,318         99.34   9,767          99.28   19,551         99.36   
  With                          196            0.66    71             0.72    125            0.64    
  **IHD**                                                                                            \< 0.001
  Without                       28,928         98.01   9,576          97.34   19,352         98.35   
  With                          586            1.99    262            2.66    324            1.65    
  **CHD**                                                                                            0.009
  Without                       29,375         99.53   9,778          99.39   19,597         99.60   
  With                          139            0.47    60             0.61    79             0.40    
  **Stroke**                                                                                         \< 0.001
  Without                       29,139         98.73   9,633          97.92   19,506         99.14   
  With                          375            1.27    205            2.08    170            0.86    
  **Cancer**                                                                                         0.999
  Without                       29,490         99.92   9,830          99.92   19,660         99.92   
  With                          24             0.08    8              0.08    16             0.08    
  **Anxiety**                                                                                        0.032
  Without                       28,925         98.00   9,620          97.78   19,305         98.11   
  With                          589            2.00    218            2.22    371            1.89    
  **Depression**                                                                                     \< 0.001
  Without                       28,952         98.10   9,455          96.11   19,497         99.09   
  With                          562            1.90    383            3.89    179            0.91    
  **Obesity**                                                                                        \< 0.001
  Without                       29,480         99.88   9,817          99.79   19,663         99.93   
  With                          34             0.12    21             0.21    13             0.07    
  **Season**                                                                                         \< 0.001
  Spring (March-May)            6,978          23.64   2,197          22.33   4,781          24.30   
  Summer (June-August)          7,580          25.68   2,499          25.40   5,081          25.82   
  Autumn (September-November)   8,021          27.18   2,907          29.55   5,114          25.99   
  Winter (December-Feburary)    6,935          23.50   2,235          22.72   4,700          23.89   
  **Urbanization level**                                                                             \< 0.001
  1 (The highest)               10,267         34.79   3,079          31.30   7,188          36.53   
  2                             12,327         41.77   3,992          40.58   8,335          42.36   
  3                             2,671          9.05    982            9.98    1,689          8.58    
  4 (The lowest)                4,249          14.40   1,785          18.14   2,464          12.52   
  **Insured premium (NT\$)**                                                                         0.068
  \< 18,000                     22,712         76.88   7,600          77.02   15,112         76.80   
  18,000--34,999                6,609          22.37   2,193          22.22   4,416          22.44   
  ≧ 35,000                      223            0.75    75             0.76    148            0.75    

*P*-value (category variable: Chi-square/Fisher exact test; continue variable: *t*-test).

The percentages of the development of comorbidities, including hypertension (6.31% vs. 3.25%; *P* \< 0.001), DM (4.66% vs. 2.73%; *P* \< 0.001), hyperlipidemia (2.07% vs. 0.80%; *P* \< 0.001), COPD (3.87% vs. 0.96%; *P* \< 0.001), IHD (2.66% vs. 1.65%; *P* \< 0.001), CHD (0.61% vs. 0.40%; *P* = 0.009), stroke (2.08% vs. 0.86%; *P* \< 0.001), anxiety (2.22% vs. 1.89%; *P* = 0.032), depression (3.89% vs. 0.91%; *P* \< 0.001), and obesity (0.21% vs. 0.07%; *P* \< 0.001) in the subject group were significantly increased compared with the control group. The percentage of individuals in the subject group who developed PPD in autumn (29.55% vs. 25.99%) was significantly increased compared with the control group (*P* \< 0.001). The percentages of level 3 (9.98% vs. 8.58%) and level 4 (18.14% vs. 12.52%) urbanization of residence in the subject group were increased compared with the control group (*P* \< 0.001).

Table [2](#T2){ref-type="table"} lists the univariate and multivariate analysis results on the influencing factors of PPD. After comorbidity, season, urbanization level, and insured premium (income) were controlled, the chance (risk) of developing PPD in pregnant women with SD was 5.359-fold (*P* \< 0.001) increased compared with the control group (pregnant women without SD).

###### Factors of postpartum depression by using cox regression

  Variables                     Crude HR    95% CI   95% CI   *P*        Adjusted HR   95% CI   95% CI   *P*
  ----------------------------- ----------- -------- -------- ---------- ------------- -------- -------- ----------
  **Sleep disorder**                                                                                     
  Without                       Reference                                Reference                       
  With                          6.253       2.863    13.655   \< 0.001   5.359         2.391    12.011   \< 0.001
  **Age group (years)**                                                                                  
  ≦ 20                          9.454       5.868    48.451   \< 0.001   7.692         4.286    33.333   \< 0.001
  21--30                        4.125       2.295    7.694    \< 0.001   3.231         2.204    4.565    \< 0.001
  31--34                        3.513       2.986    5.131    \< 0.001   2.923         2.751    3.412    \< 0.001
  35--37                        3.429       2.842    4.566    \< 0.001   2.538         2.098    3.701    \< 0.001
  38--40                        2.123       1.797    3.968    \< 0.001   1.923         1.614    2.512    \< 0.001
  ≧ 41                          Referece                                 Reference                       
  **Number of births**                                                                                   
  1 (First-time birth)          4.712       2.895    6.502    \< 0.001   3.345         2.121    4.995    \< 0.001
  ≧ 2                           Reference                                Reference                       
  **Hypertension**                                                                                       
  Without                       Reference                                Reference                       
  With                          0.000       \-       \-       0.302      0.000         \-       \-       0.600
  **DM**                                                                                                 
  Without                       Reference                                Reference                       
  With                          0.485       0.066    3.575    0.478      0.852         0.112    6.479    0.877
  **Hyperlipidemia**                                                                                     
  Without                       Reference                                Reference                       
  With                          1.798       0.245    13.223   0.564      2.837         0.364    22.125   0.320
  **COPD**                                                                                               
  Without                       Reference                                Reference                       
  With                          0.000       \-       \-       0.581      0.000         \-       \-       0.726
  **CKD**                                                                                                
  Without                       Reference                                Reference                       
  With                          0.000       \-       \-       0.689      0.000         \-       \-       0.854
  **IHD**                                                                                                
  Without                       Reference                                Reference                       
  With                          0.000       \-       \-       0.533      0.000         \-       \-       0.755
  **CHD**                                                                                                
  Without                       Reference                                Reference                       
  With                          0.000       \-       \-       0.748      0.000         \-       \-       0.854
  **Stroke**                                                                                             
  Without                       Reference                                Reference                       
  With                          0.000       \-       \-       0.632      0.000         \-       \-       0.815
  **Cancer**                                                                                             
  Without                       Reference                                Reference                       
  With                          0.000       \-       \-       0.970      0.000         \-       \-       0.646
  **Anxiety**                                                                                            
  Without                       Reference                                Reference                       
  With                          4.696       1.118    19.724   0.035      2.423         1.273    7.424    0.043
  **Depression**                                                                                         
  Without                       Reference                                Reference                       
  With                          6.478       2.480    16.924   \< 0.001   3.063         1.008    9.431    0.005
  **Obesity**                                                                                            
  Without                       Reference                                Reference                       
  With                          0.000       \-       \-       0.898      0.000         \-       \-       0.998
  **Season**                                                                                             
  Spring (March-May)            Reference                                Reference                       
  Summer (June-August)          0.580       0.206    1.629    0.301      0.513         0.181    1.459    0.211
  Autumn (September-November)   1.058       0.446    2.513    0.898      0.867         0.361    2.087    0.751
  Winter (December-Feburary)    0.324       0.088    1.195    0.091      0.306         0.082    1.134    0.076
  **Urbanization level**                                                                                 
  1 (The highest)               0.860       0.312    2.365    0.769      0.957         0.345    2.654    0.932
  2                             0.682       0.252    1.845    0.451      0.781         0.286    2.132    0.630
  3                             0.846       0.211    3.381    0.813      0.861         0.214    3.461    0.833
  4 (The lowest)                Reference                                Reference                       
  **Insured premium (NT\$)**                                                                             
  \< 18,000                     Reference                                Reference                       
  18,000--34,999                0.000       \-       \-       0.977      0.000         \-       \-       0.989
  ≧ 35,000                      5.700       0.776    41.873   0.087      6.335         0.833    48.159   0.074

HR = hazard ratio, CI = confidence interval, Adjusted HR: Adjusted variables listed in the table.

The chances (risks) of developing PPD in pregnant women at the ages of ≤ 20 years, 21--30 years, 31--34 years, 35--37 years, and 38--40 years were 7.692-fold (*P* \< 0.001), 3.231-fold (*P* \< 0.001), 2.923-fold (*P* \< 0.001), 2.538-fold (*P* \< 0.001), and 1.923-fold (*P* \< 0.001) increased compared with those ≥ 41 years. In addition, the chance (risk) of developing PPD in pregnant women with their first-time birth was 3.345-fold (*P* \< 0.010) increased compared with pregnant women with their second birth. Moreover, the chance (risk) of developing PPD in pregnant women with anxiety was 2.423-fold (*P* = 0.043) increased compared with pregnant women without anxiety, and the chance (risk) of developing PPD in pregnant women with depression was 3.063-fold (*P* = 0.005) increased compared with women without depression.

Table [3](#T3){ref-type="table"} presents the stratified analyses of all variables to identify the fold increase in the risk of developing PPD in pregnant women with SD compared with pregnant women without SD. In the population of pregnant women aged 21--30 years after other factors were controlled, the chance (risk) of developing PPD in patients with SD was 8.593-fold (*P* = 0.001) increased compared with pregnant women without SD. In the population of pregnant women aged 31--34 years, the chance (risk) of developing PPD in patients with SD was 5.911-fold (*P* = 0.027) increased compared with pregnant women without SD. Among pregnant women with their first-time birth, the risk of developing PPD in patients with SD was 10.098-fold (*P* \< 0.011) increased compared with pregnant women without SD.

###### Factors of postpartum depression stratified by variables listed in the table by using cox regression

  Sleep disorder                With   Without     Ratio    Adjusted HR   95% CI      95% CI   *P*                                
  ----------------------------- ------ ----------- -------- ------------- ----------- -------- -------- -------- ------- -------- ----------
  **Total**                     20     18,658.66   107.19   10            55,943.95   17.88    5.997    5.359    2.391   12.011   \< 0.001
  **Age group (years)**                                                                                                           
  ≦ 20                          3      1,243.95    241.17   0             1,629.89    0.00     \-       \-       \-      \-       \-
  21--30                        3      7,335.78    40.90    1             22,647.36   4.42     9.262    8.593    1.386   53.283   0.011
  31--34                        5      3,667.45    136.33   3             10,629.02   28.22    4.830    5.911    1.220   28.646   0.027
  35--37                        2      2,004.28    99.79    2             9,444.56    21.18    4.712    4.986    0.645   25.426   0.221
  38--40                        3      2,117.01    141.71   2             6,442.97    31.04    4.565    4.645    0.380   17.028   0.262
  ≧ 41                          4      2,290.19    174.66   2             5,150.15    38.83    4.498    4.266    0.017   8.116    0.343
  **Number of births**                                                                                                            
  1 (First-time birth)          18     6,442.12    279.41   8             31,469.46   25.42    10.991   10.098   3.487   66.457   \< 0.001
  ≧ 2                           2      12,216.54   16.37    2             24,474.49   8.17     2.003    1.975    0.978   3.010    0.078
  **Hypertension**                                                                                                                
  Without                       20     16,941.80   118.05   10            51,818.15   19.30    6.117    5.352    2.387   12.000   \< 0.001
  With                          0      1,716.86    0.00     0             4,125.80    0.00     \-       \-       \-      \-       \-
  **DM**                                                                                                                          
  Without                       19     17,107.84   111.06   10            52,477.96   19.06    5.828    5.169    2.282   11.710   \< 0.001
  With                          1      1,550.82    64.48    0             3,465.99    0.00     \-       \-       \-      \-       \-
  **Hyperlipidemia**                                                                                                              
  Without                       19     18,189.00   104.46   10            54,980.47   18.19    5.743    5.189    2.282   11.710   \< 0.001
  With                          1      469.66      212.92   0             963.48      0.00     \-       \-       \-      \-       \-
  **COPD**                                                                                                                        
  Without                       20     17,921.33   111.60   10            55,001.65   18.18    6.138    5.352    2.387   12.000   \< 0.001
  With                          0      737.33      0.00     0             942.30      0.00     \-       \-       \-      \-       \-
  **CKD**                                                                                                                         
  Without                       20     18,464.45   108.32   10            55,259.15   18.10    5.985    5.352    2.387   12.000   \< 0.001
  With                          0      194.21      0.00     0             684.80      0.00     \-       \-       \-      \-       \-
  **IHD**                                                                                                                         
  Without                       20     18,014.99   111.02   10            54,429.10   18.37    6.043    5.352    2.387   12.000   \< 0.001
  With                          0      643.67      0.00     0             1,514.85    0.00     \-       \-       \-      \-       \-
  **CHD**                                                                                                                         
  Without                       20     18,498.69   108.12   10            55,523.08   18.01    6.003    5.352    2.387   12.000   \< 0.001
  With                          0      159.97      0.00     0             420.87      0.00     \-       \-       \-      \-       \-
  **Stroke**                                                                                                                      
  Without                       20     18,232.62   109.69   10            55,090.86   18.15    6.043    5.352    2.387   12.000   \< 0.001
  With                          0      426.04      0.00     0             853.09      0.00     \-       \-       \-      \-       \-
  **Cancer**                                                                                                                      
  Without                       20     18,563.13   107.74   10            55,753.07   17.94    6.007    5.258    2.277   12.135   \< 0.001
  With                          0      95.53       0.00     0             190.88      0.00     \-       \-       \-      \-       \-
  **Anxiety**                                                                                                                     
  Without                       19     17,998.73   105.56   9             50,515.04   17.82    5.925    4.447    0.918   10.879   0.621
  With                          1      659.93      151.53   1             4,428.92    22.58    6.711    6.032    2.592   14.039   \< 0.001
  **Depression**                                                                                                                  
  Without                       16     17,293.65   92.52    9             53,880.66   16.70    5.539    4.829    0.114   6.039    0.853
  With                          4      1,365.01    293.04   1             2,063.29    48.47    6.046    6.652    2.750   16.088   \< 0.001
  **Obesity**                                                                                                                     
  Without                       20     18,613.67   107.45   10            55,890.63   17.89    6.005    5.352    2.387   12.000   \< 0.001
  With                          0      44.99       0.00     0             53.32       0.00     \-       \-       \-      \-       \-
  **Season**                                                                                                                      
  Spring (March-May)            7      3,707.07    188.83   2             13,228.77   15.12    12.490   6.301    1.214   32.704   0.028
  Summer (June-August)          4      4,650.99    86.00    2             14,620.77   13.68    6.287    9.060    1.422   57.171   0.020
  Autumn (September-November)   8      6,137.54    130.35   4             15,093.64   26.50    4.918    4.085    1.128   14.798   0.032
  Winter (December-Feburary)    1      4,163.06    24.02    2             13,001.27   15.38    1.562    1.803    0.038   17.081   0.890
  **Urbanization level**                                                                                                          
  1 (The highest)               6      4,965.34    120.84   4             18,074.03   22.13    5.460    4.352    1.055   17.950   0.042
  2                             6      7,927.42    75.69    5             24,438.70   20.46    3.699    2.468    0.676   9.020    0.171
  3                             2      2,087.67    95.80    1             5,090.88    19.64    4.877    4.341    0.390   48.277   0.232
  4 (The lowest)                6      3,678.23    163.12   0             8,340.34    0.00     \-       \-       \-      \-       \-
  **Insured premium (NT\$)**                                                                                                      
  \< 18,000                     20     18,189.49   109.95   9             54,323.25   16.57    6.637    5.851    2.532   13.519   \< 0.001
  18,000--34,999                0      400.19      0.00     0             1,261.30    0.00     \-       \-       \-      \-       \-
  ≧ 35,000                      0      68.98       0.00     1             359.40      278.24   0.000    0.000    \-      \-       0.990

PMs = Person-months; Adjusted HR = Adjusted Hazard ratio: Adjusted for the variables listed in Table [3](#T3){ref-type="table"}.; CI = confidence interval.

Table [4](#T4){ref-type="table"} presents the stratified analyses on postpartum time (≤ 6 weeks, 6--12 weeks, and \> 12 weeks). Regardless of postpartum time (≤ 6 weeks, 6--12 weeks, and \> 12 weeks), the risks of developing PPD in pregnant women with SD were increased, by 5.461-fold (*P* \< 0.001), 3.490-fold (*P* = 0.010), and 3.416-fold (*P* = 0.015), respectively, compared with pregnant women without SD.

###### Factors of postpartum depression stratified by differ times of postpartum in the table by using cox regression

  Sleep disorder                                   With   Without     Ratio      Adjusted HR   95% CI      95% CI   *P*                              
  ------------------------------------------------ ------ ----------- ---------- ------------- ----------- -------- ------- ------- ------- -------- ----------
  **Total**                                        20     18,658.66   107.19     10            55,943.95   17.88    5.997   5.359   2.391   12.011   \< 0.001
  **Times of postpartum**                                                                                                                            
  ≦ 1.5 months (6 weeks)                           12     1,034.79    1,159.66   3             1,241.92    241.56   4.801   5.461   1.495   19.952   \< 0.001
  \> 1.5 months (6 weeks), ≦ 3 months (12 weeks)   4      2,431.35    164.52     2             4,111.42    48.64    3.382   3.490   1.282   7.197    0.010
  \> 3 months (12 weeks)                           4      15,192.52   26.33      5             50,590.61   9.88     2.664   3.416   1.072   5.110    0.015

PMs = Person-months; Adjusted HR = Adjusted Hazard ratio: Adjusted for the variables listed in Table [3](#T3){ref-type="table"}.; CI = confidence interval.

Figure [3](#F3){ref-type="fig"} presents the cross analyses of pregnancy parity and postpartum time. The risk of developing PPD in pregnant women with their first-time pregnancy within postpartum 6 weeks was the highest and was 8.174-fold increased compared with pregnant women with their second (or greater) pregnancy at postpartum 12 weeks (or longer).

![Association between sleep disorder and postpartum depression stratified by times of postpartum and number of births by using Cox regression\
wks = weeks, Adjusted HR = Adjusted Hazard ration: Adjusted for the variables listed in Table [3](#T3){ref-type="table"} Interaction (Times of postpartum × Number of births) *P* \< 0.001.](oncotarget-09-25304-g003){#F3}

DISCUSSION {#s3}
==========

SD are a risk factor for developing PPD in women in Taiwan. SD increased the risk of developing PPD in women (the risk in cases with SD was 5.359-fold increased compared with cases without SD). In addition, regardless of postpartum time (≤ 6 weeks, 6--12 weeks, and \> 12 weeks), the chance (risk) of developing PPD was greater than 3.416-fold increased in pregnant women with SD compared with pregnant women without SD. Previous studies revealed that patients with SD are likely aware of bad health conditions or negative emotions, such as working under great stress \[[@R15], [@R21]\]. Moreover, the majority of studies also indicate that pregnant women are under great stress with their first birth due to physical and mental changes, expectations of newborns, and uncertainty of family and social welfare support \[[@R22]\]. As a result, this study demonstrates that pregnant women experiencing their first birth exhibit increased risks of developing PPD. Reduced sleep quality during pregnancy might be an important risk factor for developing PPD. Therefore, persistent relief of SD is very important.

SD are a defined as difficulty falling asleep, light sleep, and frequent periods of being awake at night with symptoms persisting for at least one month. SD are a common disease and can affect the quality of life of a normal individual \[[@R23]\]. Most current articles focus on the association between SD and pressure, shift work, and reproductive dysfunction as study topics \[[@R24]--[@R27]\] but did not perform a similar analysis on the risk of developing PPD caused by SD. This study was the first study in Taiwan relevant to this topic.

Previous studies noted that poor sleep quality was highly associated with depression \[[@R28], [@R29]\]. In addition, some studies investigated the development of mood disorders in pregnant women during the postpartum period using the Pittsburgh Sleep Quality Index. Poor sleep quality in late pregnancy increased the risk of depression recurrence. In particular, poor subjective sleep quality was highly associated with PPD symptoms \[[@R14], [@R30]\]. Furthermore, some scholars utilized wrist actigraphy and self-report surveys to study the association between sleep quality and PPD symptoms using longitudinal study surveys. The results revealed that poor sleep quality could be a risk factor for developing PPD and demonstrated that poor sleep quality in women in the early postpartum period was associated with symptoms of depression \[[@R31]\]. The above study results were similar to those in this study. Data in this study even indicated that SD increased the risk of developing PPD (regardless of postpartum time) and could be further used as an assessment item in the prenatal examinations of pregnant women.

This study demonstrated that among pregnant women with SD, the risk of developing PPD was the highest in pregnant women experiencing their first birth or at a young pregnant age, which is similar to findings in other cross-sectional studies. Studies noted that women experiencing their first birth and less than 25 years of age exhibited an increased risk of developing PPD if they had poor sleep quality or insomnia complaints during pregnancy \[[@R28], [@R32]\]. It is recommended that SD be considered an important predictive factor affecting PPD. During prenatal examinations of pregnant women, the sleep conditions of women experiencing their first birth and less than 25 years of age should be actively assessed to reduce the risk of developing PPD.

In addition, this study demonstrated that the risk of developing PPD in pregnant women with a history of depression was 3.063-fold increased compared with women without a history of this disease. These results were similar to those in studies in other countries demonstrating that SD in late pregnancy increased the recurrence of postpartum major depression (PPMD), especially in cases with a history of major depression \[[@R14]\]. The possible reason for this finding was that pregnant women in early pregnancy already began to experience different challenges of pregnancy and were persistently subjected to various pressures. If depression developed before pregnancy, the possibility of developing PPD greatly increased. In addition, poor sleep quality in late pregnancy was associated with recurrence. Furthermore, this study revealed another phenomenon: the risk of developing PPD in pregnant women with a history of anxiety was 2.423-fold increased compared with pregnant women without a history of anxiety. However, no relevant study is available for comparison in Taiwan or other countries; thus, further studies in this field should be performed.

This study has the following limitations. First, the health insurance data do not include the variable of the severity of SD. Therefore, relevant data are not available to discuss the severity of SD. Second, the associations between social demographic factors, such as age, number of births, and disease history, and PPD were analyzed. However, other psychological and social variables, such as potential influencing factors including the family support level and the education level of the pregnant women, might also affect PPD; however, these variables could not be further investigated in this study.

MATERIALS AND METHODS {#s4}
=====================

Data sources {#s4_1}
------------

This study performed analyses using data from the NHIRD of Taiwan from between January 1, 2000 and December 31, 2010. National health insurance was implemented in Taiwan in 1995. The NHIRD records the medical information of all insured, with a coverage rate of greater than 99% of the Taiwanese population. Therefore, we obtained data from the NHIRD to investigate the association between SD and PPD during this 10-year period. The diagnosis used in the NHIRD is the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).

Study design and participant sampling {#s4_2}
-------------------------------------

This study adopted the follow-up study design. New cases of pregnant women who were diagnosed with SD during pregnancy in the database were screened and selected as the study subjects in the study subject group. The study period was between January 1, 2000 and December 31, 2010. For comparison with the subject group, a control group with twice the number of subjects as the subject group with matched age, income, and number of births was selected (pregnant women without a diagnosis of SD).

Occurrence {#s4_3}
----------

All study participants were observed from the beginning of pregnancy until the development of PPD (ICD-9-CM 648.4) or until the end of this study on December 31, 2010.

Age and comorbidities {#s4_4}
---------------------

Study subjects were divided into 6 age groups (≤ 20 years, 21--30 years, 31--34 years, 35--37 years, 38--40 years, and ≥ 41 years). Comorbidities included hypertension (ICD-9-CM: 401--405), diabetes mellitus (DM; ICD-9-CM: 250), hyperlipidemia (ICD-9-CM: 272), chronic obstructive pulmonary disease (COPD; ICD-9-CM: 490--496), chronic kidney disease (CKD; ICD-9-CM: 585), ischemic heart disease (IHD; ICD-9-CM:410--414), congestive heart disease (CHD; ICD-9-CM:428--429), stroke (ICD-9-CM: 430--438), cancer (ICD-9-CM: 140--208), anxiety (ICD-9-CM: 300.00), and depression (ICD-9-CM 296.2--296.3, 300.4).

Statistical analyses {#s4_5}
--------------------

All analyses were performed using SPSS 22 software (SPSS, Inc., Chicago, IL, USA). Basic descriptive statistics included percentage, mean value, and standard deviation. Relevant study variables included age, urbanization, income, season, comorbidity, and number of births. In addition, comparisons of categorical variables (with and without SD) were performed using the Χ^2^ test. The differences between two groups were expressed using the hazard ratio (HR) and 95% confidence interval (CI). *P* \< 0.05 was used as the standard for determining significance.
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